ERX-315 Sensitizes Liver Cancer to PARP Inhibitors

San Antonio, TX – October 15, 2026 Adriana Baker, a MD PhD candidate in the laboratory of EtiraRx founder Dr. Ratna Vadlamudi at UT Health San Antonio, presented exciting new findings at the 2026 San Antonio Liver Cancer Symposium, held…

ERX-208 Disrupts DNA Repair

San Antonio, TX – October 12, 2026 We are pleased to share our new paper in Cancer Research Communications, showing that ERX-208, Etira’s LIPA-targeting compound, disrupts DNA repair in ovarian cancer cells by inducing sustained endoplasmic…